Abu Dhabi launches UAE Arts and Music Digital Archive Initiative to preserve intangible cultural heritage
The project spans 2.5 million square metres in KEZAD and aims to localise the manufacture of biologic medicines and vaccines while strengthening the UAE’s pharmaceutical security.

The Abu Dhabi Department of Economic Development, in cooperation with the Department of Health – Abu Dhabi, on Friday, November 20, 2026, announced the official launch of the Integrated Economic Zone for Pharmaceutical Industries and Biotechnology in Khalifa Economic Cities (KEZAD). The zone represents a total investment of Dh6 billion and covers an area of up to 2.5 million square metres. It aims to attract leading global pharmaceutical companies and medical research centres to localise the manufacture of biologic medicines, vaccines and precision medical supplies in the UAE, while strengthening the national and regional pharmaceutical security system in line with the highest international scientific and regulatory standards.
Advanced infrastructure and accredited clinical research laboratories
The new economic zone features industrial and logistics infrastructure specifically designed to meet the stringent requirements of the pharmaceutical sector. It includes advanced central laboratories for quality testing and pharmaceutical certification, as well as fully automated refrigerated warehouses equipped with precise temperature and humidity control systems. The zone also provides specialised facilities for clinical trials and genomic research. It is directly connected to Khalifa Port and Zayed International Airport, facilitating the rapid and efficient import of raw materials and export of pharmaceutical products to markets across the Middle East, Africa and Asia.
Investment incentives and strategic partnerships to support knowledge transfer
The zone offers investors and global companies an integrated package of incentives and facilities, including 100 per cent foreign ownership, tax and customs exemptions, and accelerated procedures for registering and approving medicines in direct coordination with the UAE’s health regulators. The zone is expected to attract more than 60 leading global biotechnology and vaccine manufacturing companies over the next three years, creating about 4,500 highly skilled specialised jobs in industrial pharmacy, bioengineering, research and development.
Strengthening the UAE’s position as a regional hub for healthcare and pharmaceutical innovation
The launch of the zone reflects the UAE’s commitment to achieving self-sufficiency in vital and strategic sectors. It also supports the objectives of the National Strategy for Industry and Advanced Technology, known as Operation 300bn, and Abu Dhabi’s economic vision of building a sustainable, knowledge-based economy driven by innovation and scientific research, while exporting high-value-added products.

